Is BMY a buy, hold, or sell?
BMY carries a valuation grade of Reduce. At a trailing P/E of 15.6, the stock trades at a 29% discount to the Healthcare sector median of 22.0x. Our discounted cash flow model produces an intrinsic range of $62–$121 — implying a +64% margin of safety at the current price of $55.60. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 11.2% earnings surprise. Analyst estimate revisions are trending upward.
What are BMY's key risk factors?
With a beta of 0.24, BMY exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -7.4% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 0.7% of total portfolio loss in the worst 5% of months. Net margins stand at 15.0%. Return on equity of 38.7% indicates highly efficient capital allocation. Debt-to-equity of 231% warrants monitoring for leverage risk.
Implied volatility of 4.3% is below realized volatility of 27.7%, potentially making options relatively cheap. Insiders have been net sellers to the tune of $4.0M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.9% of float, suggesting limited bearish conviction.
How does BMY fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — BMY carries a beta of 0.24, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all reduceings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, BMY shows the strongest co-movement with PFE (0.60), ABBV (0.52), JNJ (0.42). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all reduceings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The BMY analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning BMY’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
